Yungjin Pharm. Co., Ltd. (KRX:003520)

Yungjin Pharm. Statistics

Total Valuation

Yungjin Pharm. has a market cap or net worth of KRW 372.19 billion.

Market Cap	372.19B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Yungjin Pharm. has 182.89 million shares outstanding.

Current Share Class	182.89M
Shares Outstanding	182.89M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+1.41%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	2.09%
Float	86.95M

Valuation Ratios

The trailing PE ratio is 38.04.

PE Ratio	38.04
Forward PE	n/a
PS Ratio	2.34
PB Ratio	3.75
P/TBV Ratio	3.90
P/FCF Ratio	311.77
P/OCF Ratio	59.21
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.28.

Current Ratio	2.06
Quick Ratio	1.20
Debt / Equity	0.28
Debt / EBITDA	1.94
Debt / FCF	23.50
Interest Coverage	7.93

Financial Efficiency

Return on equity (ROE) is 9.00% and return on invested capital (ROIC) is 5.01%.

Return on Equity (ROE)	9.00%
Return on Assets (ROA)	3.63%
Return on Invested Capital (ROIC)	5.01%
Return on Capital Employed (ROCE)	7.35%
Revenue Per Employee	276.63M
Profits Per Employee	14.86M
Employee Count	559
Asset Turnover	0.94
Inventory Turnover	3.12

Taxes

In the past 12 months, Yungjin Pharm. has paid 659.02 million in taxes.

Income Tax	659.02M
Effective Tax Rate	7.17%

Stock Price Statistics

The stock price has decreased by -13.70% in the last 52 weeks. The beta is 0.88, so Yungjin Pharm.'s price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	-13.70%
50-Day Moving Average	2,012.74
200-Day Moving Average	2,077.77
Relative Strength Index (RSI)	58.11
Average Volume (20 Days)	302,127

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Yungjin Pharm. had revenue of KRW 158.79 billion and earned 8.53 billion in profits. Earnings per share was 53.49.

Revenue	158.79B
Gross Profit	59.28B
Operating Income	9.84B
Pretax Income	9.19B
Net Income	8.53B
EBITDA	14.48B
EBIT	9.84B
Earnings Per Share (EPS)	53.49

Balance Sheet

The company has 4.61 billion in cash and 28.06 billion in debt, giving a net cash position of -23.45 billion or -128.21 per share.

Cash & Cash Equivalents	4.61B
Total Debt	28.06B
Net Cash	-23.45B
Net Cash Per Share	-128.21
Equity (Book Value)	99.17B
Book Value Per Share	556.34
Working Capital	43.85B

Cash Flow

In the last 12 months, operating cash flow was 6.29 billion and capital expenditures -5.09 billion, giving a free cash flow of 1.19 billion.

Operating Cash Flow	6.29B
Capital Expenditures	-5.09B
Free Cash Flow	1.19B
FCF Per Share	6.53

Margins

Gross margin is 37.34%, with operating and profit margins of 6.20% and 5.37%.

Gross Margin	37.34%
Operating Margin	6.20%
Pretax Margin	5.79%
Profit Margin	5.37%
EBITDA Margin	9.12%
EBIT Margin	6.20%
FCF Margin	0.75%

Dividends & Yields

Yungjin Pharm. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	14.83%
Shareholder Yield	14.83%
Earnings Yield	2.29%
FCF Yield	0.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on February 19, 2004. It was a forward split with a ratio of 2.

Last Split Date	Feb 19, 2004
Split Type	Forward
Split Ratio	2

Scores

Yungjin Pharm. has an Altman Z-Score of 3.97 and a Piotroski F-Score of 6.

Altman Z-Score	3.97
Piotroski F-Score	6